key: cord-0736115-m2eiqjsh
authors: Floyd, Lauren; Elsayed, Mohamed E.; Seibt, Tobias; von Bergwelt-Baildon, Anke; Seo, Philip; Antiochos, Brendan; Kant, Sam; Morris, Adam; Dhaygude, Ajay; Schönermarck, Ulf; Geetha, Duvuru
title: SARS-CoV-2 vaccine response in ANCA associated vasculitis patients
date: 2021-12-11
journal: Kidney Int Rep
DOI: 10.1016/j.ekir.2021.12.004
sha: cbaac9d9cb0fcc6c0683916a076dcc8bed0ae864
doc_id: 736115
cord_uid: m2eiqjsh

nan

The development of COVID-19 vaccines and mass vaccination is a landmark achievement of modern medicine. Management of patients with anti-neutrophil cytoplasmic autoantibodies (ANCA) associated vasculitis (AAV) during the pandemic has been challenging. Immunosuppressive (IS) medications to control vasculitis are associated with severe COVID-19 infection and may impair immune response to the vaccine.

During the course of the pandemic, the treatment of AAV patients has varied across the world both with regards to induction of remission and maintenance treatments (1, 2) .

COVID-19 vaccination has been successfully implemented amongst patients with AAV given their vulnerability to severe infection. In our study we aim to identify correlations between serological tests carried out for anti-SARS-CoV-2 spike antibodies and immunosuppressive medications used in the management of AAV.

A total of one hundred and fifty-nine patients were included with a mean (SD) age 65 (14) years. The average time from diagnosis of AAV was seven years (± 6). Most patients (had AAV with multisystem involvement. Clinical characteristics, co-morbidities and correlation with anti-SARS-CoV-2 spike antibodies are shown in Table 1 .

In total, one hundred and fifty-five patients (97%) received full immunization with one dose of the Johnson and Johnson or both doses of Oxford-AstraZeneca or Pfizer-BioNTech mRNA or Moderna mRNA vaccines. The mean time between 1 st and 2 nd dose of Pfizer-BioNTech mRNA or Moderna mRNA vaccines was 33.7 ±19.9 days, whereas it was 75 ±25.9 days for Oxford-AstraZeneca vaccines. The mean duration between the second vaccine dose and anti-SARS-CoV-2 spike antibody measurement was 49.8 ±29.4 days across all centres.

Eighty-seven patients (55%) developed detectable anti-SARS-CoV-2 spike antibodies. Of those with available quantitative antibody values (n= 48), the median antibody titre was 1192 U/ml (IQR 109.3 -2461.5 U/ml). We did not find any significant correlation between humoral response and age, sex, race, ANCA type, type of vaccine received, co-morbidities or renal impairment (Table 1) .

A total of one hundred and forty-four patients received immunosuppression during time of their vaccination. Among those, 129 patients were treated with rituximab and half (n=64, 49.6%) of these developed anti-SARS-CoV-2 spike antibodies. (Table 1) .

The use of rituximab was significantly associated with poor humoral response to the COVID-19 vaccine and the absence of anti-SARS-CoV-2 spike antibodies (OR 0.31, CI 0.12-0.74, p=0.01), as demonstrated in Table 2 . In univariate analysis therapy with rituximab was strongly associated with poor antibody response among those patients treated within 6 months prior to the first vaccine dose (OR 0.12 (0.06, 0.25), p<0.001).

One hundred and seven patients had CD19 counts checked around the time of vaccination with 64 showing CD19 reconstitution and all of these patients developed detectable anti-spike antibodies. In univariate analysis CD19 reconstitution was significantly associated with the likelihood of a positive humoral vaccine response (OR 29.37 (11.71, 85.89), p<0.001).

The median cumulative dose of rituximab was 4000 mg (IQR 2583-6770 mg). Patients with a humoral response had received a lower dose of rituximab (3.91 g vs. 5.11 g, p=0.01) ( Table 1) . For every 1 g increase in the cumulative dose of rituximab given prior to vaccination there was a 10% reduction in the probability of anti-SARS-CoV-2 spike seroconversion (OR 0.89 (0.79, 0.99), p=0.05) (Table S1 ).

When adjusting for age, sex and eGFR, the effect of a cumulative dose of rituximab on the humoral response to the vaccine showed moderate significance. In Model 1 a cumulative dose of rituximab < 6 g was associated with developing a humoral response (OR 2.61 (1.21, 5.83), p=0.02), ( Table 2 ). In Model 2, when including the time between rituximab administration and vaccination, the cumulative dose effect of rituximab lost statistical significance (p=0.10). For every month between prior rituximab therapy and vaccination seroconversion rate increased by 8% (OR 1.08 (1.04, 1.13), p<0.001). On the final multivariable analysis (Table 2, model 3) we further adjusted for CD19 reconstitution. Our analysis demonstrates that regardless of cumulative dose or duration between last rituximab administration and vaccination, CD19 reconstitution was the best predictor for a humoral response to the vaccine (OR 49.85 (11.89, 273.33), p<0.001).

In this multi-centre study, we demonstrate a diminished immune response to the COVID-19 vaccine in patients with AAV following immunosuppression. Approximately half of our study participants developed no humoral antibody response to the COVID-19 vaccination. B-cell depleting therapy with rituximab was associated with the poorest response. The CD19 count was the strongest predictor for seroconversion, with depletion conferring a low likelihood of antibody formation. In line with this, the cumulative dose and timing of vaccination were both significant factors. Every additional gram of rituximab given conferred a poorer response with a dose limit effect of 6g and dosing more than more than 6 months prior to vaccination was associated with a seven-fold increase in the odds of seroconversion.

Similar findings with regards to vaccine timing in the context of rituximab therapy have been demonstrated by Prendecki et al (3) .

In our cohort, the cumulative dose of rituximab has a significant effect on humoral response to COVID-19 vaccination. For every 1 g increase in rituximab administered, the chance of serological conversion following vaccination reduced by 11%. This demonstrates that cumulative dosing affects humoral immunity and is an important factor in patients receiving maintenance rituximab treatment.

CD19 counts are used clinically as a measure of B cell depletion (4, 5 ) . In our patient cohort we found a significant relationship between B cell depletion at time of vaccination and lack of antibody production following vaccination, whereas patients with CD19 reconstitution were nearly 30 times more likely to respond to vaccination. Similar findings were recently reported in two smaller J o u r n a l P r e -p r o o f cohorts (6, 7 ) . In our cohort, this relationship remained significant irrespective of cumulative dose or timing of rituximab infusion in relation to the vaccination. Impaired humoral response to other vaccines such as Haemophilus influenza B, pneumococcus and hepatitis B has been demonstrated in rituximab treated patients and blunted immune response to vaccines has been shown to persist for up to 6 months after rituximab infusion ( 8,9,S1). A similar finding was seen in our cohort with less than a quarter (23%) of those who received rituximab within 6 months from their initial vaccine mounting a humoral response to the vaccine. However, those patients treated with rituximab more than 6 months before vaccination had significantly higher chances of developing antibodies.

The study was limited by its relatively small sample size, differences in cumulative IS doses type of vaccinations and serologic assays. Furthermore, T cell response to vaccination could not be determined. Despite this, our study cohort represents the so far largest study on humoral response to COVID-19 vaccine in AAV patients, the majority of whom were treated with B cell depleting therapy.

Our study demonstrates a significant negative impact of the therapy with the B cell depleting agent, rituximab on the anti-SARS-CoV-2 spike antibody response after vaccination. CD19 reconstitution was the most predictive marker of humoral response to the vaccine regardless of dose or duration of rituximab treatment. Based on these findings it is reasonable to propose that CD19 counts can be used as a marker to aid decisions on timing and anticipated response to other vaccines in patients receiving rituximab.

Methods, Table S1 and reference S1 in PDF file J o u r n a l P r e -p r o o f 

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Humoral and Tcell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Induction treatment of ANCA-associated vasculitis with a single dose of rituximab

Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients

but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia

Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists